HSV-2 VP22
Description
Product Specs
Product Science Overview
Herpes Simplex Virus-2 (HSV-2) is a significant human pathogen responsible for genital herpes. It is a member of the Alphaherpesvirinae subfamily, which includes other notable viruses such as HSV-1 and Varicella-Zoster Virus (VZV). One of the critical components of HSV-2 is the tegument protein VP22, which plays a crucial role in the virus’s life cycle and pathogenicity.
VP22 is a major tegument protein encoded by the UL49 gene of HSV-2. The tegument is a protein layer situated between the viral envelope and capsid, containing various proteins essential for viral replication and assembly . VP22 is highly expressed, with more than 2,000 copies present in each viral particle . It interacts with viral proteins, cellular proteins, and chromatin, facilitating multiple stages of the viral life cycle, including gene transcription, protein synthesis, virion assembly, and viral cell-to-cell spread .
Recombinant VP22 refers to the genetically engineered version of the VP22 protein. This recombinant form is often used in research to study the protein’s function and its interactions with other viral and host cell components. By creating recombinant VP22, scientists can investigate its role in viral replication, pathogenesis, and immune response, providing insights into potential therapeutic targets and vaccine development.
Studies have shown that VP22 plays a critical role in HSV-2 replication and pathogenicity. For instance, recombinant VP22-null mutant viruses exhibit impaired viral growth and spread in cell cultures and animal models . This highlights the importance of VP22 in the viral life cycle and its potential as a target for antiviral therapies.
Additionally, VP22 has been explored for its ability to enhance the delivery of therapeutic proteins and vaccines. Its capacity to facilitate the transport of proteins between cells makes it a valuable tool in gene therapy and vaccine development. Researchers have utilized recombinant VP22 to improve the efficacy of vaccines by enhancing antigen presentation and immune response .
